GLP ‐1 receptor agonist therapy for relapsed diabetes following 6q24‐related transient neonatal diabetes due to paternal uniparental disomy: A case report

Documenti analoghi

• Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes
  di: Phyo Than Htoo, et al.
  Pubblicazione: (2025)
• Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
  di: Renata Spezani, et al.
  Pubblicazione: (2025)
• Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
  di: Nicklas S. Klepser, et al.
  Pubblicazione: (2025)
• GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
  di: Teerapon Dhippayom, et al.
  Pubblicazione: (2025)
• Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
  di: Suleiman Al Ashi, et al.
  Pubblicazione: (2025)